trial

NRX-1074 in Early Course Schizophrenia

NCTId NCT02603458
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by NYU Langone Health
Primary completion 2020-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
—
Primary completion
2020-08
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
NRX-1074

Sponsors

NYU Langone HealthLead Sponsor
Naurex, Inc, an affiliate of Allergan plcCollaborator

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

2 total
Boston, United StatesNew York, United States

Linked catalysts

1
NRX-1074 in Early Course Schizophrenia — primary completion2020-08

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2020-08
Status
WITHDRAWN
relationships
The graph out of here
drug
NRX-1074
drug
lead_sponsor
NYU Langone Health
company
collaborator
Naurex, Inc, an affiliate of Allergan plc
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Donald C. Goff, MD
person